United States v. Saad Sakkal, M.D.

Court of Appeals for the Sixth Circuit·Decided February 24, 2022·No. 20-3880·Unpublished

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 22a0083n.06

No. 20-3880

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

FILED

) Feb 24, 2022 UNITED STATES OF AMERICA, DEBORAH S. HUNT, Clerk )

)

Plaintiff-Appellee, )

ON APPEAL FROM THE

v. )

UNITED STATES DISTRICT

)

COURT FOR THE

)

SAAD SAKKAL, M.D., SOUTHERN DISTRICT OF )

OHIO

)

Defendant-Appellant.

)

Before: ROGERS, STRANCH, and DONALD, Circuit Judges.

ROGERS, Circuit Judge.

As a physician at Lindenwald Medical Association, defendant Saad Sakkal prescribed various controlled substances to help patients manage pain. Following a Drug Enforcement Administration investigation, a grand jury indicted Sakkal on thirty-nine counts related to the illegal distribution of controlled substances, which included two charges of illegal distribution that resulted in death. Sakkal was arrested, and the district court ordered that Sakkal be held without pretrial bond. After trial, the jury convicted Sakkal on all counts except for one death count and one count of using another person’s registration number to prescribe controlled substances. Sakkal moved for a new trial and retained new counsel, who raised a claim of ineffective assistance of the previous trial counsel. Following a hearing on the question of whether previous counsel was ineffective, the district court denied Sakkal’s motion. On appeal, Sakkal argues that (1) the trial

court improperly denied him bail; (2) the evidence was not sufficient to conclude that Sakkal’s distribution of controlled substances caused a person’s death; and (3) Sakkal received ineffective assistance of counsel at the plea-bargaining stage and during trial. None of these arguments warrants reversal.

Saad Sakkal practiced medicine at Lindenwald Medical Association from February 2015 to December 2016. Sakkal was licensed to practice medicine in Ohio and also had a DEA registration number to dispense Schedule II through Schedule V controlled substances. The DEA began investigating Sakkal’s prescription practices after a referral from the Ohio Medical Board, which had received several phone calls from pharmacists about Sakkal issuing problematic prescriptions.

In June 2018, a grand jury returned a thirty-nine-count indictment against Sakkal: thirty counts of illegal distribution of a controlled substance in violation of 21 U.S.C. § 841(a)(1); two counts of distribution of a controlled substance that resulted in death in violation of 21 U.S.C. § 841(b)(1)(C); and seven counts of using the registration number of another to dispense a controlled substance in violation of 21 U.S.C. § 843(a)(2). The magistrate judge initially ordered a $250,000 bond. The Government appealed the magistrate judge’s order, and the district court overruled the magistrate judge’s determination and ordered the U.S. Marshals Service to place Sakkal in custody without bond.

At trial, the Government introduced testimony that Sakkal utilized several dangerous prescription methods. The Government’s expert, Dr. Timothy King, testified that Sakkal was prescribing multiple substances that served the same purpose and that this “therapeutic duplication” risked “significant adverse effects, including respiratory sedation and death.” Sakkal also prescribed several dangerous combinations of controlled substances, including:

(1) amphetamines and opioids; (2) methadone with a benzodiazepine and an amphetamine; and (3) opioids with a benzodiazepine and a muscle relaxant, Soma. Finally, Sakkal sometimes prescribed high amounts of controlled substances.

The Government also presented testimony that Sakkal ignored warning signs about the danger of his prescription practices. Employees at Lindenwald administered drug screens to determine if patients were taking their controlled substances as prescribed and to evaluate whether the patient was also taking illegal controlled substances. These drug screens operate as an objective method to ensure that controlled-substance prescriptions do not contribute to a risk of overdose or maintenance of an addiction. Sakkal’s records indicated that his patients’ drug screens sometimes revealed that patients were taking unprescribed controlled substances or were not taking prescribed controlled substances. Sakkal’s records never showed that he discharged or disciplined a patient because of the concerning drug screens.

Sakkal also failed to use the Ohio Automated Rx Reporting System (OARRS) to monitor his patients’ prescriptions for controlled substances. This system is designed to log all of a patient’s controlled-substance prescriptions that are filled or dispensed in Ohio. This allows a physician to ensure that patients have not already received a prescription for their ailments and to confirm that patients have not been doctor shopping to obtain controlled substances. Even when other Lindenwald employees provided Sakkal with OARRS reports for his patients, he did not review the reports.

Several pharmacies became aware of Sakkal’s prescription practices and began calling Lindenwald to discuss concerns about these practices. Sakkal met with at least three pharmacies to discuss these concerns, but he did not change his prescribing practices. Some pharmacies decided to stop filling Sakkal’s prescriptions for controlled substances.

In addition to charging Sakkal with illegal distribution of controlled substances, the indictment charged Sakkal with two counts of illegally distributing controlled substances that resulted in a patient’s death. One of these patients, Ashley Adkins, visited Sakkal for the first time in December 2015. After Sakkal conducted an examination in “medical student type fashion,” he prescribed seventeen medications for Adkins, including a “fairly high dose” of a benzodiazepine and a muscle relaxant. On January 18, 2016, an anonymous caller reported to Lindenwald that Adkins was abusing her medications and looking to sell or trade them. That same day, Adkins returned for a second appointment and reported having anxiety and pain. Her medical record from that day states: “She appears to be under the influence of either drugs or alcohol. Her speech is very slurred, her balance is off.” Despite these concerning signs, Sakkal prescribed Adkins another benzodiazepine and a low dose of oxycodone.

Following the appointment, Adkins went with her living companion, Chris Norvell, to fill her prescriptions. The two spent time together afterwards, and Adkins passed away during the night while Norvell was asleep. When Norvell woke up, he realized that Adkins had died and noticed that half the bottle of oxycodone was gone. A coroner performed an autopsy and concluded that Adkins died of benzodiazepine and oxycodone toxicity. The autopsy did not locate any fentanyl, cocaine, or marijuana in Adkins’s blood. The toxicology report indicated that Adkins’s benzodiazepine and oxycodone levels were outside the therapeutic ranges. On cross examination, however, King acknowledged that Adkins would have had appropriate levels of benzodiazepine and oxycodone in her system if she had taken Sakkal’s prescriptions as directed.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Saad Sakkal, M.D., (6th Cir. 2022).

United States v. Saad Sakkal, M.D. (United States v. Saad Sakkal, M.D.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Murphy v. Hunt
455 U.S. 478 (Supreme Court, 1982)
Strickland v. Washington
466 U.S. 668 (Supreme Court, 1984)
United States v. Williams
612 F.3d 500 (Sixth Circuit, 2010)
United States v. Jack Lyle
793 F.2d 1294 (Sixth Circuit, 1986)
Lafler v. Cooper
132 S. Ct. 1376 (Supreme Court, 2012)
Eddie D. Smith v. United States
348 F.3d 545 (Sixth Circuit, 2003)
Luis Carlos Guerrero v. United States
383 F.3d 409 (Sixth Circuit, 2004)
Burrage v. United States
134 S. Ct. 881 (Supreme Court, 2014)
United States v. Charles Adams
598 F. App'x 425 (Sixth Circuit, 2015)
United States v. Paul Volkman
797 F.3d 377 (Sixth Circuit, 2015)
John Stojetz v. Todd Ishee
892 F.3d 175 (Sixth Circuit, 2018)
Emond Logan v. United States
910 F.3d 864 (Sixth Circuit, 2018)
United States v. Jurmaine Jeffries
958 F.3d 517 (Sixth Circuit, 2020)
Ashley Bard v. Brown Cty., Ohio
970 F.3d 738 (Sixth Circuit, 2020)
United States v. Manthey
92 F. App'x 291 (Sixth Circuit, 2004)